DBV Technologies: positive follow-up data for EPITOPE

(CercleFinance.com) - DBV Technologies reports that data from its EPITOPE OLE study in one- to three-year-olds confirms that continued treatment with Viaskin Peanut results in improvement in all efficacy parameters after 36 months of treatment.


The biopharmaceutical company points out that 68.2% of subjects completed the oral challenge test without meeting the study's stopping criteria, compared with 30.7% after 12 months.

No anaphylactic reactions or treatment-related serious adverse events occurred during the third year of the EPITOPE OLE study', adds the food allergy specialist.

DBV also claims data on daily patch wear time from the EPITOPE study support the company's proposed indication to the US FDA.

Copyright (c) 2025 CercleFinance.com. All rights reserved.